News
We can see that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) does use debt in its business. But is this debt a concern to shareholders? Debt assists a business until the business has trouble paying it ...
Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...
In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.
12d
Fintel on MSNOppenheimer Upgrades Alnylam Pharmaceuticals (ALNY)
Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...
13d
Fintel on MSNWolfe Research Upgrades Alnylam Pharmaceuticals (ALNY)
Fintel reports that on August 4, 2025, Wolfe Research upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...
Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that ...
Good morning, ladies and gentlemen, and welcome to the Alnylam Q2 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, July 31, 2025. I would now like to ...
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) future prospects. Alnylam Pharmaceuticals, Inc. discovers, ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed ...
17d
Zacks.com on MSNAlnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results